After analyzing the data, he and his collaborators in Berlin are convinced that the activity
of Shp2 and its target genes can predict the outcome
of breast cancer: The less active Shp2 is, the
higher the
chance for the affected women to stay
relapse - free after having undergone a successful breast cancer therapy.